Dr. Peter Heinrich, Chief Executive Officer

Dr. Peter Heinrich is the chief executive officer of MagForce Nanotechnologies AG, serving as chairman of the management board. Prior to this Dr. Peter Heinrich was co-founder of MediGene AG and served as its managing director and CEO from 1995 until the middle of 2009. MediGene is a biotechnology company listed on the Frankfurt Stock Exchange and included in the TecDax index which at that time was focused on the development of innovative pharmaceuticals in the fields of oncology/immunology and cardiology. In his long career with the company, Dr. Heinrich initially served as CEO/managing director and sole executive board member with responsibility for all areas. Following the company’s stock exchange listing in 2000 and expansion of its executive board, he held specific board-level responsibility for the areas of administration, business development, controlling, corporate finance, investor and public relations, organizational development, intellectual property and human resources, along with executive responsibility for the company’s facilities in San Diego (California) and Oxford (UK). Under the leadership of Dr. Heinrich, MediGene grew from a venture capital-financed start-up to an established biopharmaceutical company with international operations and drugs on the market. Along the way, Dr. Heinrich played a key role in achieving a number of noteworthy milestones in the company’s development, including the regulatory approval and market launches of the drugs Eligard®, Veregen® and Oracea®, the acquisition of companies, the in- licensing and out-licensing of drug candidates, strategic partnerships with pharmaceutical corporations, the company’s listing on the Frankfurt Stock Exchange in 2000 as well as follow-on capital market transactions.

Prior to his achievements at MediGene, Dr. Heinrich worked for almost eight years at Wacker Chemie AG in Munich, where he held several positions in management and in biotechnology research and development. During this time he was substantially involved in the development of biotechnology products which have since been successfully brought to market. Following his studies in biology and chemistry at the University of Munich, where he received his doctoral degree in biochemistry, Dr. Heinrich continued with post-doctoral work at Harvard University. He is co-founder and chairman of the executive board of BIO-Deutschland, an independent organization representing the interests of the German biotechnology industry. From 2001 to 2009 he served as a member of European Biopharmaceutical Enterprises (EBE), including as its president from 2003 to 2006. Dr. Heinrich also serves on the board of trustees of Bayern Innovativ GmbH, as a mentor and tutor at the Bavarian Elite Academy, and on the supervisory board of the University of Augsburg’s MBA program.

Dr. Andreas Jordan, Founder & Chief Scientific Officer

Dr. Andreas Jordan founded MagForce Nanotechnologies AG and serves on its management board as chief scientific officer, with responsibility for all research and development activities. He began his career with studies in biology at the Free University of Berlin, followed by further studies in biochemistry at the Technical University of Berlin. His highly praised doctoral dissertation in 1993 addressed the production of nanoparticles and their application for cancer therapy. This pioneering work was based on research which began in 1987, long before the subject of nanotechnology had achieved any international significance. He subsequently managed scientific projects for the Berlin’s Virchow Clinic (now Charité) as well as for the Institute for Diagnostic Research, a subsidiary of Schering.

Dr. Jordan has already delivered more than 500 scientific lectures about Nano-Cancer^® therapy. He has authored more than 45 articles for peer-reviewed scientific journals and has cleared the way for twelve families of international patents, some of which have been licensed. His contacts to NASA, the National Cancer Institute (NCI), the Institute of Nanotechnology (IoN), the U.S. Food and Drug Administration (FDA), and such renowned U.S. hospitals as the University of California, San Francisco (UCSF), the Cleveland Clinic Foundation (CCF) and Duke University, as well as throughout Asia, continue to provide an essential foundation for his professional activities through the world.